Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer

HANDLE オープンアクセス

抄録

BACKGROUND: Mesothelin is expressed in various types of malignant tumour, and we recently reported that expression of mesothelin was related to an unfavourable patient outcome in pancreatic ductal adenocarcinoma. In this study, we examined the clinicopathological significance of the mesothelin expression in gastric cancer, especially in terms of its association with the staining pattern. METHODS: Tissue specimens from 110 gastric cancer patients were immunohistochemically examined. The staining proportion and intensity of mesothelin expression in tumour cells were analysed, and the localisation of mesothelin was classified into luminal membrane and/or cytoplasmic expression. RESULTS: Mesothelin was positive in 49 cases, and the incidence of mesothelin expression was correlated with lymph-node metastasis. Furthermore, luminal membrane staining of mesothelin was identified in 16 cases, and the incidence of luminal membrane expression was also correlated with pT factor, pStage, lymphatic permeation, blood vessel permeation, recurrence, and poor patient outcome. Multivariate analysis showed that luminal membrane expression of mesothelin was an independent predictor of overall patient survival. CONCLUSION: We described that the luminal membrane expression of mesothelin was a reliable prognostic factor in gastric cancer, suggesting the functional significance of membrane-localised mesothelin in the aggressive behaviour of gastric cancer cells. British Journal of Cancer (2012) 107, 137-142. doi: 10.1038/bjc.2012.235 www.bjcancer.com Published online 29 May 2012 (C) 2012 Cancer Research UK

収録刊行物

関連プロジェクト

もっと見る

詳細情報 詳細情報について

  • CRID
    1050845763940983424
  • NII論文ID
    120005158911
  • HANDLE
    2115/51715
  • ISSN
    00070920
  • 本文言語コード
    en
  • 資料種別
    journal article
  • データソース種別
    • IRDB
    • CiNii Articles
    • KAKEN

問題の指摘

ページトップへ